# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Machinaton	$D \subset$	20E 40	
Washington,	D.C.	20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Bender Jeremy						2. Issuer Name and Ticker or Trading Symbol  Day One Biopharmaceuticals, Inc. [ DAWN ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) 2000 SIE		oate o		iest Tra	nsaction	(Mon	nth/Day/Year)		X Officer (give title below) Other (specification)  Chief Executive Officer										
(Stroot)					4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Cl Line)									g (Check	Applicable				
(Street) BRISBA	.NE C	A !	94005	5	_											One Reporting Person More than One Reporting			
(City)	(Si	tate)	(Zip)		Rı	Rule 10b5-1(c) Transaction Indication													
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date		2. Transacti Date (Month/Day	/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 au			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Owners (Indirect Process)				
									Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common	Stock			05/15/20	)23				M		3,562	A	(1)	1,177	7,838	D			
Common	Stock			05/15/20	)23				M		4,750	A	(1)	1,182	32,588 D				
Common	Stock			05/16/20	)23				S <sup>(2)</sup>		3,104	D	\$13.122	3 1,179	9,484	184 D			
Common	Stock													281,574 I See Footno				See Footnote <sup>(3)</sup>	
Common	Stock													281,574 I See Footno					
		Ta	able I	II - Deriva (e.g., p							posed of			y Owned					
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Ex- curity or Exercise (Month/Day/Year) if		Execu	Deemed 4. oution Date, Tra		action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Exerc			nd of s ng e Security	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reported Transact (Instr. 4)	ve es ally ig d tion(s)	10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership tt (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Units	(1)	05/15/2023			M			3,562	(5	)	(5)	Common Stock	3,562	\$0.00	35,6	528 г			
Restricted Stock Units	(1)	05/15/2023			M			4,750	(5)	)	(5)	Common Stock	4,750	\$0.00	66,5	,500			

## Explanation of Responses:

- 1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
- 2. The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
- 3. Represents shares held by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person is trustee.
- 4. Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.
- 5. The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

## Remarks:

/s/ Charles N. York II, as Attorney-in-Fact

05/17/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.